Therapeutic Drug Monitoring of Sirolimus: Effect of Concomitant Immunosuppressive Therapy and Optimization of Drug Dosing

Sirolimus (SRL) is a new immunosuppressant which shares a common metabolic pathway with several other immunosuppressive agents. This leads to potential pharmacokinetic interactions that might affect SRL blood levels with relevant clinical consequences. As a validated laboratory, 2658 SRL trough samples (corresponding to 495 kidney transplant recipients treated with different immunosuppressive regimens) from more than 40 Italian Transplant Units were analyzed. We found that dose‐normalized SRL trough levels were significantly higher in patients treated with cyclosporine (CsA) and SRL (4.15 ± 2.23 ng/mL/mg SRL), compared with patients treated with mycophenolate mofetil (MMF) and SRL (3.26 ± 1.86 ng/mL/mg SRL; p < 0.01) or with MMF, steroids and SRL (2.52 ± 1.73 ng/mL/mg SRL; p < 0.01). Mean intra‐ and interpatient variabilities were 19% and 47%, respectively. Both parameters are significantly affected by the time postsurgery, with the first week post transplantation being associated with the greatest variability. As additional analysis, a simple dose‐adjustment formula has been proposed as a useful tool to guide SRL dose changes. The proposed equation has been able to predict SRL concentration after a dose change in 73% of the tested samples. These findings suggest that different immunosuppressants significantly interfere with SRL bioavailability. Strategies aimed at reducing variability in SRL exposure may have a positive clinical impact.

[1]  N. Perico,et al.  From Pharmacokinetics to Pharmacogenomics: A New Approach to Tailor Immunosuppressive Therapy , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[2]  J. Gaynor,et al.  A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year , 2004, Transplantation.

[3]  P. Beaune,et al.  Pharmacokinetic interaction between corticosteroids and tacrolimus after renal transplantation. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[4]  J. Fung,et al.  Phenytoin Decreases the Blood Concentrations of Sirolimus in a Liver Transplant Recipient: A Case Report , 2003, Therapeutic drug monitoring.

[5]  K. Brouwer,et al.  Cytokine Regulation of P-Glycoprotein , 2003, Drug metabolism reviews.

[6]  F. Schena,et al.  Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination1, 2 , 2002, Transplantation.

[7]  Matthew J Cervelli.  Fluconazole-sirolimus drug interaction. , 2002, Transplantation.

[8]  D. Holt.  Therapeutic drug monitoring of immunosuppressive drugs in kidney transplantation , 2002, Current opinion in nephrology and hypertension.

[9]  N. Plant,et al.  Glucocorticoid-mediated induction of CYP3A4 is decreased by disruption of a protein: DNA interaction distinct from the pregnane X receptor response element. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[10]  N. Perico,et al.  Assessment of sirolimus concentrations in whole blood by high-performance liquid chromatography with ultraviolet detection. , 2002, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[11]  J. Morales,et al.  Sirolimus steady-state trough concentrations are not affected by bolus methylprednisolone therapy in renal allograft recipients. , 2002, British journal of clinical pharmacology.

[12]  Vivian Charles McAlister,et al.  A Clinical Pharmacokinetic Study of Tacrolimus and Sirolimus Combination Immunosuppression Comparing Simultaneous to Separated Administration , 2002, Therapeutic drug monitoring.

[13]  K. Midtvedt,et al.  Recommendations for the Implementation of Neoral C2 Monitoring in Clinical Practice , 2002, Transplantation.

[14]  Dietmar Stöckl,et al.  Application of the Bland-Altman plot for interpretation of method-comparison studies: a critical investigation of its practice. , 2002, Clinical chemistry.

[15]  Atholl Johnston,et al.  Therapeutic drug monitoring of immunosuppressant drugs in clinical practice. , 2002, Clinical therapeutics.

[16]  J. Pascussi,et al.  Dual effect of dexamethasone on CYP3A4 gene expression in human hepatocytes. Sequential role of glucocorticoid receptor and pregnane X receptor. , 2001, European journal of biochemistry.

[17]  P. Taylor,et al.  From Beach to Bedside: History of the Development of Sirolimus , 2001, Therapeutic drug monitoring.

[18]  R. Oberbauer,et al.  Sirolimus Allows Early Cyclosporine Withdrawal in Renal Transplantation Resulting in Improved Renal Function and Lower Blood Pressure. , 2001 .

[19]  R. Oberbauer,et al.  SIROLIMUS ALLOWS EARLY CYCLOSPORINE WITHDRAWAL IN RENAL TRANSPLANTATION RESULTING IN IMPROVED RENAL FUNCTION AND LOWER BLOOD PRESSURE1,2,10 , 2001, Transplantation.

[20]  S. Stepkowski,et al.  EFFECT OF LOW DOSE CYCLOSPORINE AND SIROLIMUS ON HEPATIC DRUG METABOLISM IN THE RAT1 , 2001, Transplantation.

[21]  B. Kahan,et al.  Combination treatment with sirolimus and ciclosporin in clinical renal transplantation: A comprehensive review. , 2001, Drugs of today.

[22]  B D Kahan,et al.  Pharmacokinetic interactions augment toxicities of sirolimus/cyclosporine combinations. , 2001, Journal of the American Society of Nephrology : JASN.

[23]  S. Stepkowski,et al.  EFFECT OF LOW DOSE CYCLOSPORINE AND SIROLIMUS ON HEPATIC DRUG METABOLISM IN THE RAT , 2001 .

[24]  P. Hansten,et al.  Long-term safety of hepatic hydroxymethyl glutaryl coenzyme A reductase inhibitors: the role of metabolism-monograph for physicians. , 2000, Archives of internal medicine.

[25]  J. Squifflet,et al.  Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. , 2000, Transplantation.

[26]  J. Podbielski,et al.  Therapeutic drug monitoring of sirolimus: correlations with efficacy and toxicity , 2000, Clinical transplantation.

[27]  D. Holt,et al.  Proficiency-testing issues relating to sirolimus. , 2000, Clinical therapeutics.

[28]  J. Zimmerman,et al.  Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus. , 2000, Clinical therapeutics.

[29]  J. Miller.  Sirolimus approved with renal transplant indication. , 1999, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[30]  H. Meier‐Kriesche,et al.  The effects of relative timing of sirolimus and cyclosporine microemulsion formulation coadministration on the pharmacokinetics of each agent , 1998, Clinical pharmacology and therapeutics.

[31]  W. Jusko,et al.  Pharmacokinetics of Prednisolone During Administration of Sirolimus in Patients with Renal Transplants , 1996, Journal of clinical pharmacology.

[32]  L. Langman,et al.  Pharmacodynamic monitoring of immunosuppressive drugs. , 1996, Transplantation proceedings.

[33]  B D Kahan,et al.  Effects of the pharmacokinetic interaction between orally administered sirolimus and cyclosporine on the synergistic prolongation of heart allograft survival in rats. , 1996, Transplantation.

[34]  D. Holt,et al.  Consensus Guidelines for Therapeutic Drug Monitoring of Rapamycin: Report of the Consensus Panel , 1995, Therapeutic drug monitoring.

[35]  J. Kay,et al.  Inhibition of T and B lymphocyte proliferation by rapamycin. , 1991, Immunology.

[36]  D. Altman,et al.  STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT , 1986, The Lancet.

[37]  S. Sehgal,et al.  Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. , 1975, The Journal of antibiotics.

[38]  S. Sehgal,et al.  Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. , 1975, The Journal of antibiotics.

[39]  A. Beckett,et al.  AKUFO AND IBARAPA. , 1965, Lancet.